Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?

Company Overview - Alnylam Pharmaceuticals (ALNY) shares increased by 5.3% to $165.70, with a notable trading volume, reflecting a 5.4% gain over the past four weeks [1][2] - The rise in stock price is attributed to investor optimism regarding Amvuttra's (vutrisiran) revenue potential, which recorded sales of $195 million in Q1 2024, a 92% increase [2] Financial Performance - Alnylam is expected to report a quarterly loss of $0.78 per share, representing a year-over-year change of +64.7%, with revenues projected at $450.23 million, up 41.3% from the previous year [3] - The consensus EPS estimate has been revised slightly higher in the last 30 days, indicating a positive trend that may lead to stock price appreciation [3] Industry Context - Alnylam operates within the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Acadia Pharmaceuticals (ACAD), whose stock rose by 3.7% to $15.30 [4] - Acadia's consensus EPS estimate has decreased by 2.8% over the past month, but shows a significant year-over-year change of +1500% [4]